Bronchiectasis is an irreversible condition in adults. In children and adolescents, it may be reversible with early detection and effective treatment, thereby avoiding the later deterioration in lung function.[9]Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021 Aug;58(2):2002990.
https://erj.ersjournals.com/content/58/2/2002990.long
http://www.ncbi.nlm.nih.gov/pubmed/33542057?tool=bestpractice.com
The typical disease course consists of periods of symptom control interrupted by periods of exacerbations. Bronchiectasis frequently coexists with other respiratory disease, making it difficult to determine prognosis for bronchiectasis alone.[128]Keistinen T, Saynajakangas O, Tuuponen T, et al. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J. 1997 Dec;10(12):2784-7.
http://erj.ersjournals.com/content/10/12/2784.full.pdf
http://www.ncbi.nlm.nih.gov/pubmed/9493661?tool=bestpractice.com
Factors associated with a faster decline in lung function include more frequent severe exacerbations.[129]Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007 Nov;132(5):1565-72.
http://www.ncbi.nlm.nih.gov/pubmed/17998359?tool=bestpractice.com
Hypoxemia, hypercapnia, dyspnea, and radiographic extent of disease have been shown to correlate with mortality. Conversely, a higher body mass index, regularly scheduled doctor visits, and vaccinations improve survival.[75]Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007 Jul;101(7):1390-7.
http://www.ncbi.nlm.nih.gov/pubmed/17374480?tool=bestpractice.com
The Bronchiectasis Severity Index, validated in the UK and Europe, may help with understanding prognosis and guiding treatment in adults.[111]Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977711
http://www.ncbi.nlm.nih.gov/pubmed/24328736?tool=bestpractice.com
[112]Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J. 2016 Feb;47(2):482-9.
http://www.ncbi.nlm.nih.gov/pubmed/26585428?tool=bestpractice.com
[113]McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016 Dec;71(12):1110-8.
http://thorax.bmj.com/content/71/12/1110.long
http://www.ncbi.nlm.nih.gov/pubmed/27516225?tool=bestpractice.com
The following factors have been shown by multivariate analysis to independently predict mortality in patients with moderate to severe bronchiectasis:[130]Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long term study assessing the factors influencing survival. Eur Respir J. 2009 Oct;34(4):843-9.
http://www.ncbi.nlm.nih.gov/pubmed/19357155?tool=bestpractice.com
Pseudomonas aeruginosa infection
Male sex
Advanced age
Higher residual volume/total lung capacity ratio
Increased wall thickness on computed tomography imaging
Low activity level score as judged by St. George's Respiratory Questionnaire.
Quality of life
According to the St. George Respiratory Questionnaire, dyspnea, reduced forced expiratory volume in the first second of expiration (FEV₁), and daily sputum production have the greatest impact on the quality of life in patients with bronchiectasis.[131]Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005 Aug;128(2):739-45.
http://journal.publications.chestnet.org/article.aspx?articleid=1083558
http://www.ncbi.nlm.nih.gov/pubmed/16100162?tool=bestpractice.com
Patients and parents responding to the European Lung Foundation survey reported that exacerbations were one of the top factors that affected the child’s quality of life.[9]Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021 Aug;58(2):2002990.
https://erj.ersjournals.com/content/58/2/2002990.long
http://www.ncbi.nlm.nih.gov/pubmed/33542057?tool=bestpractice.com
Pseudomonas species in sputum
Pseudomonas species in the sputum of patients with bronchiectasis indicates more extensive lung disease and more severe impairment of pulmonary function than in patients without Pseudomonas species colonization. Some studies have shown that Pseudomonas species colonization is an independent factor associated with a faster decline in lung function. Evidence is conflicting.[129]Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007 Nov;132(5):1565-72.
http://www.ncbi.nlm.nih.gov/pubmed/17998359?tool=bestpractice.com